JP2013523704A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523704A5
JP2013523704A5 JP2013501930A JP2013501930A JP2013523704A5 JP 2013523704 A5 JP2013523704 A5 JP 2013523704A5 JP 2013501930 A JP2013501930 A JP 2013501930A JP 2013501930 A JP2013501930 A JP 2013501930A JP 2013523704 A5 JP2013523704 A5 JP 2013523704A5
Authority
JP
Japan
Prior art keywords
virus
solution
additive
alkyl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523704A (ja
JP5869553B2 (ja
Filing date
Publication date
Priority claimed from GBGB1005517.6A external-priority patent/GB201005517D0/en
Priority claimed from GBGB1005521.8A external-priority patent/GB201005521D0/en
Priority claimed from GBGB1017648.5A external-priority patent/GB201017648D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/000493 external-priority patent/WO2011121301A1/en
Publication of JP2013523704A publication Critical patent/JP2013523704A/ja
Publication of JP2013523704A5 publication Critical patent/JP2013523704A5/ja
Application granted granted Critical
Publication of JP5869553B2 publication Critical patent/JP5869553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501930A 2010-03-31 2011-03-31 ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤 Active JP5869553B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1005517.6A GB201005517D0 (en) 2010-03-31 2010-03-31 Stabilised liquid formulations of polypeptides
GBGB1005521.8A GB201005521D0 (en) 2010-03-31 2010-03-31 Stabilised liquid formulations of virus particles
GB1005517.6 2010-03-31
GB1005521.8 2010-03-31
GBGB1017648.5A GB201017648D0 (en) 2010-10-19 2010-10-19 Liquid preparation containing stabilised viruses
GB1017648.5 2010-10-19
PCT/GB2011/000493 WO2011121301A1 (en) 2010-03-31 2011-03-31 Excipients for stabilising viral particles, polypeptides or biological material

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016001536A Division JP6053969B2 (ja) 2010-03-31 2016-01-07 ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤

Publications (3)

Publication Number Publication Date
JP2013523704A JP2013523704A (ja) 2013-06-17
JP2013523704A5 true JP2013523704A5 (cg-RX-API-DMAC10.html) 2014-04-17
JP5869553B2 JP5869553B2 (ja) 2016-02-24

Family

ID=43902836

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013501930A Active JP5869553B2 (ja) 2010-03-31 2011-03-31 ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
JP2016001536A Active JP6053969B2 (ja) 2010-03-31 2016-01-07 ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016001536A Active JP6053969B2 (ja) 2010-03-31 2016-01-07 ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤

Country Status (15)

Country Link
US (2) US20130164296A1 (cg-RX-API-DMAC10.html)
EP (1) EP2552478B1 (cg-RX-API-DMAC10.html)
JP (2) JP5869553B2 (cg-RX-API-DMAC10.html)
KR (2) KR101943429B1 (cg-RX-API-DMAC10.html)
CN (1) CN102892427A (cg-RX-API-DMAC10.html)
AU (2) AU2011234264B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012025047A2 (cg-RX-API-DMAC10.html)
CA (1) CA2795047C (cg-RX-API-DMAC10.html)
DK (1) DK2552478T3 (cg-RX-API-DMAC10.html)
ES (1) ES2617921T3 (cg-RX-API-DMAC10.html)
GB (1) GB2490644A (cg-RX-API-DMAC10.html)
HU (1) HUE033656T2 (cg-RX-API-DMAC10.html)
IL (1) IL221857A (cg-RX-API-DMAC10.html)
WO (1) WO2011121301A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201206956B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
GB201117233D0 (en) * 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
EP3559239B1 (en) 2016-12-22 2024-09-25 Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK) Oligomeric vaccines from plants by s-tag-s-protein fusions
WO2018127702A1 (en) * 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
KR101878599B1 (ko) * 2017-03-28 2018-07-13 전북대학교산학협력단 메틸설포닐메테인과 만니톨의 흡수촉진 및 고미감소를 위한 공침조성물과 이의 제조방법
GB2562241B (en) * 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR113996A1 (es) * 2017-12-22 2020-07-08 Intervet Int Bv Vacunas líquidas de virus envueltos vivos
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
JP7712284B2 (ja) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物
CN114649066B (zh) * 2020-12-17 2025-02-11 南开大学 一种提升d-氨基酸减缓mbr膜污染效能的智能优化方法
JP7748616B2 (ja) * 2021-03-24 2025-10-03 大日本印刷株式会社 液体入り組合せ容器、容器セットおよび液体入り容器の製造方法
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) * 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) * 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US4980277A (en) 1987-10-16 1990-12-25 Cultor Ltd. Cryoprotectant solution and method
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
DE69032102T2 (de) 1989-08-15 1998-06-25 Massachusetts Inst Technology Stabilisierte impfstoffzusammensetzungen
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
RU2099418C1 (ru) * 1991-11-21 1997-12-20 Лонца Аг Фрагмент днк, обеспечивающий использование бетаина, рекомбинантная плазмидная днк с фрагментом днк, обеспечивающим использование бетаина, штамм бактерий rhizobium/agrobacterium, предназначенный для стабильного хранения плазмиды с фрагментом днк, способ получения штамма бактерий
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
FR2698879B1 (fr) 1992-12-09 1995-01-13 Rhone Poulenc Biochimie gellules modifiées au niveau du catabolisme de la bétaïne, préparation et utilisations, notamment pour la production de métabolites ou d'enzymes.
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5965438A (en) * 1995-06-07 1999-10-12 Phyton, Inc. Cryopreservation of plant cells
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9521806D0 (en) * 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US6037116A (en) 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
AU5459698A (en) 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AUPQ347199A0 (en) * 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
CA2412197A1 (en) 2000-06-08 2001-12-13 Powderject Vaccines, Inc. Powder compositions
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
AU2002302814A1 (en) 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
DE60329070D1 (de) 2001-12-28 2009-10-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen den fibroblastenwachstumsfaktor 23
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
JP2003261591A (ja) 2002-03-08 2003-09-19 Koji Hayade 凍結乾燥安定剤
WO2004002534A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
WO2004007537A2 (en) 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated to cellular receptors
AU2003272174A1 (en) 2002-10-21 2004-05-04 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
EP1638993A4 (en) 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
EP1711619A4 (en) 2003-12-30 2007-04-11 Virumar Pituach Tarkivin Ltd INTEGRATED VIRUS COMPLEXES, METHOD FOR THE MANUFACTURE THEREOF, VACCINES CONTAINING THEM AND METHOD FOR THE USE THEREOF
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
MX2007003968A (es) 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
EP1824460B1 (en) 2004-11-10 2014-12-24 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
AU2006249640C1 (en) 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
ME01965B (me) 2005-09-16 2012-04-30 Merial Ltd Stabilizatori za vakcine osušene zamrzavanjem
EP2324850A1 (en) 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
WO2007095337A2 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
ES2286951B1 (es) 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
US20090053197A1 (en) 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
US20090047255A1 (en) * 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
GB0705245D0 (en) * 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP2829282B1 (en) 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2150537A4 (en) 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
CN101801404A (zh) 2007-06-29 2010-08-11 先进科技及再生医学有限责任公司 供在高温下使用的蛋白质配方
CA2693827A1 (en) 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
JP5599778B2 (ja) 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシー 液体緩衝ｇｄｆ−５製剤
CA2721800A1 (en) * 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
US20110212127A1 (en) * 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
AU2009295623A1 (en) * 2008-09-24 2010-04-01 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
WO2010146598A2 (en) 2008-11-07 2010-12-23 Serum Institute Of India Ltd. Stable, dried rotavirus vaccine, compositions and process for preparation thereof
CA2761675A1 (en) 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
DK2552410T3 (en) 2010-03-31 2019-02-18 Stabilitech Biopharma Ltd PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
WO2018127702A1 (en) 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions

Similar Documents

Publication Publication Date Title
JP2013524782A5 (cg-RX-API-DMAC10.html)
JP2016539921A5 (cg-RX-API-DMAC10.html)
JP2008533007A5 (cg-RX-API-DMAC10.html)
RU2016119746A (ru) Стабильный состав инсулина глулизин
EP2552478B1 (en) Excipients for stabilising viral particles
JP2015537020A5 (cg-RX-API-DMAC10.html)
JP2013523677A5 (cg-RX-API-DMAC10.html)
JP2017531619A5 (cg-RX-API-DMAC10.html)
JP2018504420A5 (cg-RX-API-DMAC10.html)
JP2012051891A5 (cg-RX-API-DMAC10.html)
JP2014521744A5 (cg-RX-API-DMAC10.html)
JP2016534153A5 (cg-RX-API-DMAC10.html)
JP2014129360A5 (cg-RX-API-DMAC10.html)
JP2013523676A5 (cg-RX-API-DMAC10.html)
MX378901B (es) Formulaciones liquidas estables de virus de vacuna.
JP2014520852A5 (cg-RX-API-DMAC10.html)
JP2013543505A5 (cg-RX-API-DMAC10.html)
RU2012124985A (ru) Лекарственная форма для комбинации hgh и rhigf-1
MX360727B (es) Composiciones y metodos para evitar la agregacion del vector aav.
BR112020012632A2 (pt) vacinas líquidas de vírus envelopados vivos
IL274897B1 (en) Formulations of dengue virus vaccine compositions
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
EA201390810A1 (ru) Жидкие вирусные составы
JP2015051983A5 (cg-RX-API-DMAC10.html)
RU2017112303A (ru) Способ применения комбинации нового производного гидроксамовой кислоты и антибактериального вещества